Twenty-six study participants were counseled to follow a reduced calorie, lower-fat diet, and then took alli three times per day for 12 weeks. Results also showed that at week 12 alli significantly reduced waist circumference (the measurement around the waistline), the best practical way to assess visceral fat, by 5 cm (2 inches).

The Visceral Fat Multi-Center StudyIn the six-month Visceral Fat Multi-Center Study, overweight and obese adults receiving alli while on a reduced calorie, lower-fat diet had significantly greater improvements in visceral fat than those treated with diet alone.

In this study, 123 participants were randomly assigned to receive either alli three times per day or a placebo, along with recommendations to follow a reduced calorie, lower-fat diet, for 24 weeks. At week 24, statistically significant reductions in visceral fat and body weight were observed in both groups; however, the reduction was significantly higher among patients taking alli. Mean reductions in visceral fat were 15.66 percent for alli versus 9.39 percent for placebo (P<0.0001); mean reductions in body weight were 5.96 kg versus 3.91 kg, respectively (P<0.05).

Overweight and obese people enrolled in the Visceral Fat Imaging Study and Visceral Fat Multi-Center Study had a body mass index (BMI) of 25-35 kg/m2, with a waist circumference greater than 88 cm (34.64 inches) for women or 102 cm (40.16 inches) for men at the start of the studies. Use of alli in both studies was shown to be generally well tolerated and consistent with the known safety profile.

alli is marketed by GlaxoSmithKline Consumer Healthcare for use by overweight adults along with a reduced calorie, lower-fat diet. People interested in losing weight can access interactive tools, lower-fat recipes, physical activity tips and other useful information for leading a healthy life at www.myalli.